The Use of Peptide-Based Diet in Enteral Nutrition Therapy: A Retrospective Cost Analysis
Osman Mohamed Elfadil, MBBS, Ankitaben Patel, MBBS, Raj N. Shah, MBBS, Ryan T. Hurt, MD, PhD, Manpreet S. Mundi, MD
Journal of Parenteral and Enteral Nutrition 2023;47(S2):S18.
Background:
Home enteral nutrition (HEN) is often used to provide long-term nutrition therapy. Enteral feeding intolerance (EFI) is prevalent in HEN patients and often requires transition to a peptide-based tube feeding formula (PBF).
Objective:
Determine the economic impact of using specialized formulas for the treatment of EFI in the HEN population.
Methods:
This was a retrospective analysis of the Mayo Clinic Rochester HEN population data, evaluating the cost of transitioning to a PBF during therapy from October 2018 through August 2020, with evaluation of demographic data, enteral nutrition (EN) regimen and cost of care being captured through October of 2020 or termination of EN. Cost of care was categorized as follows:
— Emergency Department visits-ED
— Inpatient care-IP
— Outpatient care-OP
— Total cost of care-TC
Results:
• 60 patients included
• Mean age 53.5 ± 20.7 years
• 55% female
• Disease Process:
— Malignancy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43.3%
— Hepato-biliary/Pancreatic. . . . . . . . . . . . . . . . . 15.0%
— Mucosal Disease. . . . . . . . . . . . . . . . . . . . . . . . 10.0%
— Non-Malignant Mechanical
Obstruction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8.4%
— Bariatric Surgery . . . . . . . . . . . . . . . . . . . . . . . . . 8.4%
— Gastrointestinal Dysmotility. . . . . . . . . . . . . . . . 6.6%
— Neurodengerative/Developmental Delay. . . . . 6.6%
— Functional Disorder. . . . . . . . . . . . . . . . . . . . . . . 1.7%
• Indication for EN included dysphagia/odynophagia,
malnutrition, nausea and vomiting, fistula or bowel
perforation, inadequate oral intake or obstruction/
stricture.
• Pre-transition prevalence of EFI was.....................43.3%
• Post-transition prevalence of EFI was...................21.6%
Conclusion:
Use of PBD improves EFI and results in a reduction in overall and itemized total cost of care.
Study funded by Nestlé Health Science.
Summary prepared by Nestlé Health Science. All trademarks are owned by Société des Produits Nestlé S.A., Vevey, Switzerland. ©2023 Nestlé Health Science. All rights reserved.